Jonsson A-S, Flodin M, Hansson L-O, Larsson A
Department of Clinical Chemistry, Karlstad, Sweden.
Scand J Clin Lab Invest. 2007;67(8):801-9. doi: 10.1080/00365510701397538.
Estimation of glomerular filtration rate (eGFR) is essential in the diagnosis and monitoring of patients with kidney disease and for correct dosage of drugs eliminated from the circulation by the kidneys. Cystatin C has been shown in several studies to be superior to creatinine in estimating eGFR. However, there are few studies on the performance of cystatin C estimated eGFR (eGFRCystC) in patients with advanced kidney disease and low GFR.
We measured serum cystatin C, together with serum creatinine, during iohexol clearance in patients with iohexol clearance below 30 mL/min/1.73 m2. The cystatin C values were used to calculate eGFRCystC using the formula eGFR (mL/min/1.73 m2) = 79.901*(cystatin C value in mg/L)-1.4389.
There was good correlation between eGFRCystC and iohexol clearance (r = 0.88) in patients with iohexol clearance <30 mL/min/1.73 m2 and none of the patients had a difference between eGFRCystC and iohexol clearance exceeding 50 %. The Modification of Diet in Renal Disease (MDRD) equation and corrected MDRD eGFR showed a positive bias and weaker correlations with iohexol eGFR (MDRD = 5.32+1.22iohexol clearance; corrected MDRD = 4.76+1.10iohexol clearance; r = 0.59). For MDRD eGFR, 42 of 94 (44.7%) samples showed more than 50% difference to iohexol clearance.
eGFRCystC is an efficient, practical and cost-effective alternative to iohexol clearance in patients with reduced GFR.
估算肾小球滤过率(eGFR)对于肾病患者的诊断和监测以及正确确定经肾脏从循环中清除的药物剂量至关重要。多项研究表明,在估算eGFR方面,胱抑素C优于肌酐。然而,关于晚期肾病且肾小球滤过率(GFR)较低患者中胱抑素C估算的eGFR(eGFRCystC)性能的研究较少。
我们在碘海醇清除率低于30 mL/min/1.73 m²的患者进行碘海醇清除试验期间,测量了血清胱抑素C和血清肌酐。使用公式eGFR(mL/min/1.73 m²)= 79.901×(胱抑素C值,单位为mg/L)⁻¹.4389,根据胱抑素C值计算eGFRCystC。
碘海醇清除率<30 mL/min/1.73 m²的患者中,eGFRCystC与碘海醇清除率之间存在良好的相关性(r = 0.88),且没有患者的eGFRCystC与碘海醇清除率差异超过50%。肾脏病饮食改良(MDRD)方程和校正后的MDRD eGFR显示出正偏差,与碘海醇eGFR的相关性较弱(MDRD = 5.32 + 1.22×碘海醇清除率;校正后的MDRD = 4.76 + 1.10×碘海醇清除率;r = 0.59)。对于MDRD eGFR,94个样本中有42个(44.7%)与碘海醇清除率的差异超过50%。
对于GFR降低的患者,eGFRCystC是替代碘海醇清除率的一种有效、实用且具有成本效益的方法。